CASIA OpenIR  > 中国科学院分子影像重点实验室
Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging
Liang, Qian1,2,3; Kong, Lingxin1,2,3; Du, Yang1,2,3; Zhu, Xu4; Tian, Jie1,2,3,5,6
发表期刊EXPERIMENTAL AND MOLECULAR MEDICINE
ISSN1226-3613
2019-07-08
卷号51页码:11
通讯作者Du, Yang(yang.du@ia.ac.cn) ; Zhu, Xu(drzhuxu@163.com) ; Tian, Jie(jie.tian@ia.ac.cn)
摘要Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. Sorafenib is the standard first-line treatment for advanced HCC, but its efficacy is limited. Apatinib is a small-molecule tyrosine kinas e inhibitor that has shown promising antitumor effects in gastric and non-small cell lung cancers in clinical trials, but there have been only a few studies reporting its anti-HCC effects in vitro and in HCC xenograft models. Hence, our present study systemically investigated and compared the antitumorigenic and antiangiogenic efficacy of apatinib and sorafenib in HCC in vitro and in vivo using multimodality molecular imaging, including bioluminescence imaging (BLI), bioluminescence tomography (BLT), fluorescence molecular imaging (FMI), and computed tomography angiography ( CTA). Moreover, the safety and side effects of the two drugs were systemically evaluated. We found that apatinib showed a comparable therapeutic efficacy to sorafenib for the inhibition of HCC. The drug safety evaluation revealed that both of these drugs caused hypertension and mild liver and kidney damage. Sorafenib caused diarrhea, rash, and weight loss in mice, but these effects were not observed in mice treated with apatinib. In conclusion, apatinib has similar antitumorigenic and antiangiogenic efficacy as sorafenib in HCC with less toxicity. These findings may provide preclinical evidence supporting the potential application of apatinib for the treatment of HCC patients.
DOI10.1038/s12276-019-0274-7
关键词[WOS]HEPATOCELLULAR-CARCINOMA ; THERAPY ; ANGIOGENESIS ; TOMOGRAPHY ; MODELS ; TUMORS
收录类别SCI
语种英语
资助项目National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science and Technology Commission[Z161100002616022] ; National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science and Technology Commission[Z161100002616022]
项目资助者National Key Research and Development Plan of China ; National Natural Science Foundation of China ; Strategic Priority Research Program from Chinese Academy of Sciences ; International Innovation Team of CAS ; Beijing Municipal Science and Technology Commission
WOS研究方向Biochemistry & Molecular Biology ; Research & Experimental Medicine
WOS类目Biochemistry & Molecular Biology ; Medicine, Research & Experimental
WOS记录号WOS:000474511300002
出版者NATURE PUBLISHING GROUP
七大方向——子方向分类其他
引用统计
被引频次:21[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.ia.ac.cn/handle/173211/26901
专题中国科学院分子影像重点实验室
通讯作者Du, Yang; Zhu, Xu; Tian, Jie
作者单位1.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Beijing 100190, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100080, Peoples R China
3.Beijing Key Lab Mol Imaging, Beijing 100190, Peoples R China
4.Peking Univ, Dept Intervent Therapy, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Sch Oncol, 52 Fucheng Rd, Beijing 100142, Peoples R China
5.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Med, Beijing 100191, Peoples R China
6.Xidian Univ, Engn Res Ctr Mol & Neuro Imaging, Sch Life Sci & Technol, Minist Educ, Xian 710126, Shaanxi, Peoples R China
第一作者单位中国科学院自动化研究所;  中国科学院分子影像重点实验室
通讯作者单位中国科学院自动化研究所;  中国科学院分子影像重点实验室
推荐引用方式
GB/T 7714
Liang, Qian,Kong, Lingxin,Du, Yang,et al. Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging[J]. EXPERIMENTAL AND MOLECULAR MEDICINE,2019,51:11.
APA Liang, Qian,Kong, Lingxin,Du, Yang,Zhu, Xu,&Tian, Jie.(2019).Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.EXPERIMENTAL AND MOLECULAR MEDICINE,51,11.
MLA Liang, Qian,et al."Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging".EXPERIMENTAL AND MOLECULAR MEDICINE 51(2019):11.
条目包含的文件 下载所有文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
s12276-019-0274-7.pd(2847KB)期刊论文作者接受稿开放获取CC BY-NC-SA浏览 下载
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liang, Qian]的文章
[Kong, Lingxin]的文章
[Du, Yang]的文章
百度学术
百度学术中相似的文章
[Liang, Qian]的文章
[Kong, Lingxin]的文章
[Du, Yang]的文章
必应学术
必应学术中相似的文章
[Liang, Qian]的文章
[Kong, Lingxin]的文章
[Du, Yang]的文章
相关权益政策
暂无数据
收藏/分享
文件名: s12276-019-0274-7.pdf
格式: Adobe PDF
此文件暂不支持浏览
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。